Preliminary data from the phase I NX-5948-301 study for NX-5948 demonstrated an ORR of 76.7% in patients with R/R CLL characterized by high-risk features, including central nervous system involvement, prior exposure to BTK and BCL2 inhibitors including pirtobrutinib (97.1% of patients had prior BTK inhibitor therapy, 91.2% had prior BCL2 inhibitor therapy, and 23.5% had prior exposure to pirtobrutinib), TP53 mutations (40.4%), and BTK mutations (38.6%) [100]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.